Market
Adaptimmune, after bringing cell therapy to market, questions viability and defunds 2 preclinical programs
Adaptimmune, Tecelra, Viable, Market, Solid Neoplasm, cellular targeting
Federal Circuit ruling allows Amgen’s Eylea biosimilar to stay on the market
Market, Amgen ‘s, Pavblu, Amgen, Eylea biosimilar, Regeneron, Federal Circuit, court, Eylea
Six Payer Trends Shaping Market Access in 2025
Market, trends qualifier, Access, Enrollment, 2025, payer, Shapes, payers, Artificial Intelligence
Mixed pivotal data for Pfizer, Arvinas’ protein degrader in breast cancer
Pfizer, Vepdegestrant, Clinical Trials, ESR1 gene, Statistical Significance, Improvement, Progression-Free Survival, Market
5 Market Access Mistakes That Can Derail Your EU Orphan Drug Launch
EU, Market, Access, Failed, NR4A2 gene
Biotech M&A Heats Up: Cosette’s $430M Mayne Pharma Acquisition and Industry-Wide Stock Buybacks
Biotech acquisitions, pharmaceutical mergers, stock repurchase programs, women’s health, dermatology, market consolidation
Biotech IPO Momentum: Maze and Metsera’s Dual Debut Signals Renewed Market Optimism
Biotech IPOs, Maze Therapeutics, Metsera, obesity treatment, precision medicine, market optimism, 2025 IPO trends
Sanofi’s Beyfortus Achieves Blockbuster Status, Poised for Further Growth in US Market
Beyfortus, RSV antibody, Sanofi, blockbuster sales, US market growth, infant protection, respiratory syncytial virus
Rentschler Biopharma Exits Cell and Gene Therapy Sector, Refocuses on Biologics Manufacturing
Rentschler Biopharma, strategic realignment, cell and gene therapy, biologics manufacturing, CDMO, market demand, Stevenage facility closure
Sionna and Odyssey Therapeutics Kick Off 2025 Biotech IPO Wave with SEC Filings
Sionna Therapeutics, Odyssey Therapeutics, IPO filings, biotech industry, JPM Healthcare Conference, 2025 IPO market